Sentences with phrase «many big pharma»

Not only is the science around them advancing quickly, but the drugs are so complex that they are hard for generic producers to copy — an attractive prospect for big pharma.

«There are two ways to receive validation: from partnerships with big pharma and from smart investors,» Bloom says.

The lines between Big Pharma and small biotech are eroding.

The goal was to stop anti-competitive practices in legal settlements by established players in Big Pharma.

The advantage of Zymeworks» strategy is that licensing platforms to big pharma entitles it to a combination of cash up front, milestone payments as the clients» research proceeds and potential royalties once one of the drugs developed on the platform reaches the market.

Should Big Pharma be nervous?

Big pharma's return on investment vis - a-vis R&D plummeted to a dismal 3.2 % in 2017 compared with 10.1 % in 2010.

In that regard, the picture above is worth a thousand words: Nearly all of Big Pharma is riding on fumes, it seems.

Big pharma is a popular target for righteous anger from many quarters, but Governor Brown's defense of the law rests on reducing income inequality rather than sticking it to the man for its own sake.

For instance, legislators like Sens. Elizabeth Warren of Massachusetts, Bernie Sanders of Vermont, and Jeff Merkley of Oregon recently warned that Cures amounts to a big pharma giveaway which will weaken regulatory standards on drugs, provide a mere pittance to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), and do nothing to confront the rising tide of high drug prices.

According to Industry Canada, Big Pharma spends more than $ 1.3 billion a year on R&D — and many global drug makers are increasingly looking at Canada for top talent and a cost - competitive advantage over the United States.

It's the biggest health reform legislation passed by Congress since Obamacare and has galvanized a similarly motley crew of industries and lobbying outfits — including big pharma (the legislation's most ardent proponent), patient advocacy groups, mental health organizations, and medical researchers — who fought for its passage over the last three years.

Doing so, says Gartner biotech analyst Stephen Davies, will require forging still closer ties to big pharma firms — the lumbering giants whose inefficiency spurred Wojcicki to action in the first place.

CNBC's Meg Tirrell discuss what to expect from big pharma companies reporting earnings tomorrow including Pfizer and Merck.

She speculates that the company strengthened its bonds with customers by taking a stand against Big Pharma.

Valeant CEO Mike Pearson said in a conference call that Medicis will strengthen the company's place in medical dermatology and bring it to critical mass in aesthetics, a $ 12 - billion market that doesn't depend on government health - plan reimbursement and previously did not have a significant «big pharma» presence.

In the last few years, the number of clinical trials in this field has exploded, along with the flurry of money from Big Pharma and investors, stirring optimism in the fight against cancer.

For one, big pharma's supply chain is a global enterprise with global ambitions, and manufacturing is cheaper in countries like India and China.

* Second biggest pharma deal after Pfizer / Warner Lambert.

The report points to a number of factors driving big pharma companies» struggles with netting strong returns, including a dearth of late - stage pipeline candidates and diversified product portfolios that aren't necessarily spreading risk.

He wasn't surprised that startup CEOs spoke up while the major players did not: «There are a lot more ways for the Trump administration to hurt Big Pharma firms with products on the market than there are ways for the Trump administration to hurt biotech firms.»

LONDON — Japanese drugmaker Takeda has reached a tentative agreement to buy Ireland - based Shire for 46 billion pounds in one of the biggest pharma deals to date.

And the tactic isn't all that surprising: big pharma's return on R&D investments has been plummeting over the last decade, and price increases are an easy way to bolster companies» bottom lines.

Specialty pharmacies — pharmacies that act as a separate distribution and billing mechanism for big drug firms — aren't unheard of in the world of big pharma, but Valeant's relationship with Philidor was strangely close.

Big Pharma is an active accomplice.

No doubt, you'll find EMBAs from Goldman Sachs and big pharma on the list.

As an exec at Shire (shpg), which with $ 6 billion in revenue is one of the smaller Big Pharmas, he spent months persuading leaders and commercial and supply - chain people to launch a clinical trial for the ADHD drug Vyvanse to treat binge eating.

Many of the recent Big Pharma deals and acquisition proposals have been motivated by the companies» desire to lower their tax rate by acquiring a foreign rival and moving their headquarters overseas in a process known as an inversion.

«Biotech is becoming more important than ever to Big Pharma and becoming the fuel source for their drug pipelines,» says Nicholson, who once scouted for such acquisitions at Merck.

The growing charge has led many to wonder: Will the opioid crisis hand Big Pharma its Big Tobacco moment?

And that's sad, because West Virginia is the poster child for how big pharma used its power and influence to shove drugs down people's throats.

People object to a system that they see as being dominated by big pharma, a system that intrusively asserts control over our lives, telling us what's wrong with us, and telling us what we must do in order to get better (as they choose to define «better»).

Imagine you don't like the way your physician is imposing his view of the world for you, and worry that his view is unduly influenced by the the marketing dollars of big pharma.

Big pharma has been a persistent villain in the public's consciousness over the past year in the wake of exorbitant drug price hikes, including on ancient medications.

The Novartis and Pear Therapeutics partnership follows a trend that has been a growing within big pharma.

One day I came home from working at a big pharma company that had the same type of elevator as my condo building in Toronto.

Trump meets with big pharma CEOs and issues a list of demands.

Concerns over these patent expiries, coupled with the recession, caused many investors to flee Big Pharma stocks altogether.

In immuno - oncology — what might seem a classic «biotech - y» niche in Big Pharma — Bristol might actually need some heft to be a market leader.

China, specifically, is promising for Big Pharma because people there trust brand names.

At a moment when the world's fourth - largest pharmaceutical company by sales (Pfizer) is eagerly courting the world's ninth - largest (the very same AstraZeneca from which Bristol decoupled)-- offering, in late May, a monumental dowry of around $ 120 billion — one can be forgiven for not noticing the more substantive change that's sweeping the pharmaceutical industry: Big Pharma is getting smaller.

But to those paying close attention, blockchain has all the potential in the world to disrupt some very old, very big industries: banking, big pharma, insurance, voting, and entertainment, to name a few.

Poon manages the fastest - growing business in Big Pharma, which accounts for about half of Johnson & Johnson's $ 42 billion in sales.

«I absolutely believe that if EpiPen had to be the catalyst to show this window of what families are facing in a high - deductible plan... then it would have been worth it,» the controversial big pharma chief told attendees at the Forbes Healthcare summit on Thursday.

The role that big pharma plays in research, while valuable, is often tenuous, because profit models for many diseases are not always apparent, at least in the short term.

And Big Pharma names like Merck, Sanofi, and Astra - Zeneca, are already taking it to the lab.

Immuno - oncolocy has been the focus of Big Pharma and biotechs alike, with companies such as Merck (mrk), Bristol - Myers Squibb (bmy), Pfizer (pfe), Roche / Genentech, Juno (juno), Kite Pharma (kite), Novartis (nvs), and countless others pouring massive investments into the space (the Loncar ETF contains almost all of these companies).

While Tesaro is remaining publicly coy for now, a buyout has always been in the cards as big pharma companies continue to snap up biotechs that have already done drug development legwork for them.

And a big pharma chief has topped it for the second year running.

We cover biopharma companies end - to - end — whether they're small, specialty drugmakers, generics companies or the biggest of Big Pharma — highlighting the accomplishments and acknowledging the defeats that all of them experience in the complicated, competitive pharmaceuticals industry.